NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 160 filers reported holding NEVRO CORP in Q1 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,020,536 | -40.9% | 209,185 | -21.8% | 0.02% | -38.5% |
| Q2 2023 | $6,803,434 | -33.2% | 267,641 | -5.0% | 0.04% | -37.1% |
| Q1 2023 | $10,189,781 | +12.6% | 281,875 | +23.3% | 0.06% | +1.6% |
| Q4 2022 | $9,050,184 | +107.5% | 228,540 | +144.2% | 0.06% | +79.4% |
| Q3 2022 | $4,361,000 | +3.2% | 93,583 | -2.9% | 0.03% | +3.0% |
| Q2 2022 | $4,226,000 | -40.2% | 96,414 | -1.4% | 0.03% | -31.2% |
| Q1 2022 | $7,071,000 | -33.7% | 97,762 | -25.7% | 0.05% | -32.4% |
| Q4 2021 | $10,672,000 | +652.6% | 131,640 | +980.4% | 0.07% | +610.0% |
| Q3 2021 | $1,418,000 | -31.4% | 12,184 | -2.2% | 0.01% | -28.6% |
| Q2 2021 | $2,066,000 | +18.9% | 12,460 | 0.0% | 0.01% | +7.7% |
| Q1 2021 | $1,738,000 | – | 12,460 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |